UK markets open in 4 hours 41 minutes

BerGenBio ASA (0RU5.L)

LSE - LSE Delayed price. Currency in NOK
Add to watchlist
0.1442-0.0153 (-9.62%)
At close: 03:02PM BST
Full screen
Previous close0.1595
Open0.0000
Bid0.0000 x N/A
Ask0.0000 x N/A
Day's range0.0000 - 0.0000
52-week range
Volume244,701
Avg. volume238,757
Market cap35,336
Beta (5Y monthly)1.44
PE ratio (TTM)N/A
EPS (TTM)-3.5040
Earnings date29 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • PR Newswire

    BerGenBio Announces NCI Clinical Collaboration with UT Health San Antonio and Sobi®

    BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announced today that it has entered into a clinical trial agreement with the Mays Cancer Center at The University of Texas Health Science Center at San Antonio (UT Health San Antonio) and Swedish Orphan Biovitrum AB (Sobi®) (STO:SOBI), a specialized international biopharmaceutical company.

  • PR Newswire

    BerGenBio Announces Initiation of Phase 2a in First Line Non-Small Lung Cancer Patients with a STK11 mutation

    BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announced today it has initiated the Phase 2a portion of the BGBC016 clinical study of its selective AXL inhibitor bemcentinib in combination with standard of care therapy in first-line Non Small Cell Lung Cancer (NSCLC) patients harboring a STK11 mutation (STK11m).

  • PR Newswire

    BerGenBio Announces New Preclinical Data Indicating Broadened Potential for Bemcentinib to Treat Severe Respiratory Infections

    BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced that Dr. Mirella Spalluto of the University of Southampton today presented "Investigating the effects of AXL inhibition during respiratory viral infections" during the 6th Forum on Respiratory Infections in Glasgow, Scotland.